Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 21

Sort by

Sort Order Select

Journal Articles

Correlation of Baseline Gene Mutations With Quizartinib Efficacy in Patients With FLT3 -ITD-Positive Newly Diagnosed Acute Myeloid Leukemia in the Phase 3 QuANTUM-First Trial

Blood (2024) 144 (Supplement 1): 848.

https://doi.org/10.1182/blood-2024-203303

Published: 2024

Journal Articles

Trial in Progress: The Phase 3, Randomized, Double-Blind, Placebo-Controlled QuANTUM-Wild Study of Quizartinib in Combination With Chemotherapy and as Single-Agent Maintenance in Newly Diagnosed, FLT3 -ITD-Negative Acute Myeloid Leukemia

Blood (2024) 144 (Supplement 1): 1504.3.

https://doi.org/10.1182/blood-2024-205101

Published: 2024

Journal Articles

Anchored Matching Adjusted Indirect Treatment Comparison of Quizartinib Vs Midostaurin in Newly Diagnosed Patients with FLT3-ITD-Positive Acute Myeloid Leukaemia

Nishan Shaik, Harry P. Erba, Sudhir Unni, Svenja Petersohn, Elizabeth Westerberg, Boris Gorsh, Akash Nahar, Kristy Burns, Sonja Kroep

Blood (2024) 144 (Supplement 1): 1509.

https://doi.org/10.1182/blood-2024-209799

Published: 2024

Journal Articles

131 I-Apamistamab-Led Allogeneic Hematopoietic Cell Transplant Significantly Improves Overall Survival in Patients with TP53 Mutated R/R AML

Blood (2023) 142 (Supplement 1): 469.

https://doi.org/10.1182/blood-2023-182177

Published: 2023

Journal Articles

131 I-Apamistamab Effectively Achieved Durable Responses in Patients with R/R AML Irrespective of the Presence of Multiple High-Risk Factors

Blood (2023) 142 (Supplement 1): 2159.

https://doi.org/10.1182/blood-2023-187433

Published: 2023

Journal Articles

High-Dose Targeted Radiation with 131 I-Apamistamab Prior to HCT Demonstrated a Dose-Response for Durable Complete Remission in Patients with R/R AML

Blood (2023) 142 (Supplement 1): 3529.

https://doi.org/10.1182/blood-2023-189040

Published: 2023

Journal Articles

Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti-LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma

Nathalie A. Johnson, David Lavie, Peter Borchmann, Gareth P. Gregory, Alex F. Herrera, Leonard Minuk, Vladan Vucinic, Philippe Armand, Abraham Avigdor, Robin Gasiorowski, Yair Herishanu, Colm Keane, John Kuruvilla, John Palcza, Pallavi Pillai, Akash Nahar, John Timmerman

Blood (2022) 140 (Supplement 1): 6540–6542.

https://doi.org/10.1182/blood-2022-166846

Published: 2022

Journal Articles

Waveline-001: Updated Results from a Phase 1 Dose Escalation and Cohort Expansion Study of Zilovertamab Vedotin (MK-2140) in Non-Hodgkin Lymphoma

Stephen E. Spurgeon, Matthew Mei, Paul M. Barr, Jacqueline C. Barrientos, Sven de Vos, Richard R. Furman, Krish Patel, Philip A. Thompson, Michael Y. Choi, Avyakta Kallam, Sirou Wang, Uzor C. Ogbu, Akash Nahar, Michael L. Wang

Blood (2022) 140 (Supplement 1): 6640–6641.

https://doi.org/10.1182/blood-2022-163509

Published: 2022

Journal Articles

Pembrolizumab and Chemotherapy in Newly-Diagnosed, Early Unfavorable or Advanced Stage Classic Hodgkin Lymphoma: The Phase 2 Keynote-C11 Study

Ranjana H. Advani, Abraham Avigdor, Anna Sureda, David Lavie, Stefan Hohaus, Jan M. Zaucha, Vu Minh Hua, Vittorio Ruggero Zilioli, Raimundo Gazitua, Muhit Özcan, Amos Odeleye-Ajakaye, Uzor C. Ogbu, Akash Nahar, Jane N. Winter

Blood (2022) 140 (Supplement 1): 1759–1760.

https://doi.org/10.1182/blood-2022-163787

Published: 2022

Journal Articles

Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti-LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma after Anti-PD-1 Treatment

John Timmerman, David Lavie, Nathalie A. Johnson, Abraham Avigdor, Peter Borchmann, Charalambos Andreadis, Ali Bazargan, Gareth P. Gregory, Colm Keane, Inna Tsoran-Rosenthal, Vladan Vucinic, Pier Luigi Zinzani, Rachel Marceau West, Pallavi Pillai, Akash Nahar, Alex F. Herrera

Blood (2022) 140 (Supplement 1): 768–770.

https://doi.org/10.1182/blood-2022-166670

Published: 2022

Journal Articles

Early-Stage Unfavorable Hodgkin Lymphoma: Patient Characteristics in Real-World Oncology Data from the United States

Santosh Gautam, Shweta Yeola, Akash Nahar, Eric Sarpong, Jennifer Prescott, Xiaoqin Yang, Helmneh Sineshaw

Blood (2022) 140 (Supplement 1): 12026.

https://doi.org/10.1182/blood-2022-157820

Published: 2022

Journal Articles

Pembrolizumab and Chemotherapy As First-Line Treatment of Patients with Newly Diagnosed Early Unfavorable or Advanced-Stage Classical Hodgkin Lymphoma: The Phase 2 Keynote-C11 Study

Jane N. Winter, Akash Nahar, Eunhee Kim, Patricia Marinello

Blood (2021) 138 (Supplement 1): 1379.

https://doi.org/10.1182/blood-2021-147276

Published: 2021

Journal Articles

Healthcare Resource Utilization and Cost in Patients with Relapsed/Refractory Classical Hodgkin's Lymphoma Who Received Autologous Stem Cell Transplantation in the US

Xiaoqin Yang, PhD, Kaushal D Desai, PhD MS, Adrienne M Gilligan, PhD, Monika Raut, Akash Nahar

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-136328

Published: 2020

Journal Articles

Real-World Conditional Survival Analysis of Patients with Relapsed/Refractory Classical Hodgkin's Lymphoma in the US

Kaushal D Desai, PhD MS, Xiaoqin Yang, PhD, Adrienne M Gilligan, PhD, Yeran Li, PhD, Monika Raut, Akash Nahar

Blood (2020) 136 (Supplement 1): 24–25.

https://doi.org/10.1182/blood-2020-136424

Published: 2020

Journal Articles

Effect of Pembrolizumab Monotherapy Versus Brentuximab Vedotin (BV) on Symptoms Associated with Health-Related Quality of Life (HRQoL) in Relapsed/Refractory (R/R) Classical Hodgkin Lymphoma (cHL) in the Randomized, Phase 3, Keynote-204 Study

Pier Luigi Zinzani, MD, Radhakrishnan Ramchandren, Armando Santoro, Ewa Paszkiewicz-Kozik, Robin Gasiorowski, Nathalie A Johnson, MD PhD, José S. R. de Oliveira, Valeria Buccheri, Guilherme Fleury Perini, Michael Dickinson, DMed Sci, Andrew McDonald, Muhit Ozcan, Naohiro Sekiguchi, Monika Raut, Hilde Giezek, Akash Nahar, John Kuruvilla, MD

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-139416

Published: 2020

Journal Articles

Effect of Pembrolizumab (Pembro) Monotherapy Versus Brentuximab Vedotin (BV) on Patients (Pts) with Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL): Exploratory Analysis of the Randomized, Phase 3 Keynote-204 Study By Prior Lines of Therapy

John Kuruvilla, MD, Radhakrishnan Ramchandren, Armando Santoro, Ewa Paszkiewicz-Kozik, Robin Gasiorowski, Nathalie A Johnson, MD PhD, Laura Maria Fogliatto, Iara Goncalves, José de Oliveira, Valeria Buccheri, Guilherme Fleury Perini, Neta Goldschmidt, Irina Kryachok, Naohiro Sekiguchi, Jianxin Lin, Akash Nahar, Patricia Marinello, Pier Luigi Zinzani, MD

Blood (2020) 136 (Supplement 1): 12.

https://doi.org/10.1182/blood-2020-142565

Published: 2020

Journal Articles

Phase 1-2 Study of Pembrolizumab Combined with the Anti-LAG-3 Antibody MK-4280 for the Treatment of Hematologic Malignancies

Philippe Armand, Pier Luigi Luigi Zinzani, MD, John Palcza, Jane Anne Healy, Akash Nahar, Patricia Marinello, Gareth P Gregory, MBBS (Hons), PhD FRACP, FRCPA

Blood (2019) 134 (Supplement_1): 1548.

https://doi.org/10.1182/blood-2019-127474

Published: 2019

Journal Articles

Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087

Robert Chen, Pier Luigi Zinzani, Hun Ju Lee, Philippe Armand, Nathalie A. Johnson, Pauline Brice, John Radford, Vincent Ribrag, Daniel Molin, Theodoros P. Vassilakopoulos, Akihiro Tomita, Bastian von Tresckow, Margaret A. Shipp, Jianxin Lin, Eunhee Kim, Akash Nahar, Arun Balakumaran, Craig H. Moskowitz

Blood (2019) 134 (14): 1144–1153.

https://doi.org/10.1182/blood.2019000324

Published: 2019

Includes: Supplemental data

Journal Articles

Two-Year Follow-up of Keynote-087 Study: Pembrolizumab Monotherapy in Relapsed/Refractory Classic Hodgkin Lymphoma

Pier Luigi Zinzani, MD, Robert W. Chen, MD, Hun Ju Lee, MD, Philippe Armand, MD PhD, Nathalie A Johnson, MD PhD, Pauline Brice, MD, John Radford, MD FRCP, Vincent Ribrag, MD, Daniel Molin, Theodoros P. Vassilakopoulos, MD PhD, Akihiro Tomita, MD PhD, Bastian Von Tresckow, MD, Margaret A. Shipp, MD, Eunhee Kim, Akash Nahar, MD MPH, Arun Balakumaran, MD PhD SM, Craig H. Moskowitz, MD

Blood (2018) 132 (Supplement 1): 2900.

https://doi.org/10.1182/blood-2018-99-117045

Published: 2018

Journal Articles

Pembrolizumab Antitumor Activity in Relapsed/Refractory Classical Hodgkin Lymphoma in Keynote-087: Revised Response Criteria for Malignant Lymphoma 2007 Criteria Versus Lugano 2014 Classification

Craig H. Moskowitz, MD, Robert W. Chen, MD, Philippe Armand, MD PhD, Pier Luigi Zinzani, MD, Theodoros P. Vassilakopoulos, MD PhD, Gregory V. Goldmacher, MD PhD MBA, Jianxin Lin, MS, Akash Nahar, MD MPH, Arun Balakumaran, MD PhD SM, Gilles Salles, MD PhD

Blood (2017) 130 (Supplement 1): 4085.

https://doi.org/10.1182/blood.V130.Suppl_1.4085.4085

Published: 2017

NARROW

Correlation of Baseline Gene Mutations With Quizartinib Efficacy in Patients With FLT3 -ITD-Positive Newly Diagnosed Acute Myeloid Leukemia in the Phase 3 QuANTUM-First Trial

Trial in Progress: The Phase 3, Randomized, Double-Blind, Placebo-Controlled QuANTUM-Wild Study of Quizartinib in Combination With Chemotherapy and as Single-Agent Maintenance in Newly Diagnosed, FLT3 -ITD-Negative Acute Myeloid Leukemia

Anchored Matching Adjusted Indirect Treatment Comparison of Quizartinib Vs Midostaurin in Newly Diagnosed Patients with FLT3-ITD-Positive Acute Myeloid Leukaemia

131 I-Apamistamab-Led Allogeneic Hematopoietic Cell Transplant Significantly Improves Overall Survival in Patients with TP53 Mutated R/R AML

131 I-Apamistamab Effectively Achieved Durable Responses in Patients with R/R AML Irrespective of the Presence of Multiple High-Risk Factors

High-Dose Targeted Radiation with 131 I-Apamistamab Prior to HCT Demonstrated a Dose-Response for Durable Complete Remission in Patients with R/R AML

Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti-LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma

Waveline-001: Updated Results from a Phase 1 Dose Escalation and Cohort Expansion Study of Zilovertamab Vedotin (MK-2140) in Non-Hodgkin Lymphoma

Pembrolizumab and Chemotherapy in Newly-Diagnosed, Early Unfavorable or Advanced Stage Classic Hodgkin Lymphoma: The Phase 2 Keynote-C11 Study

Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti-LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma after Anti-PD-1 Treatment

Early-Stage Unfavorable Hodgkin Lymphoma: Patient Characteristics in Real-World Oncology Data from the United States

Pembrolizumab and Chemotherapy As First-Line Treatment of Patients with Newly Diagnosed Early Unfavorable or Advanced-Stage Classical Hodgkin Lymphoma: The Phase 2 Keynote-C11 Study

Healthcare Resource Utilization and Cost in Patients with Relapsed/Refractory Classical Hodgkin's Lymphoma Who Received Autologous Stem Cell Transplantation in the US

Real-World Conditional Survival Analysis of Patients with Relapsed/Refractory Classical Hodgkin's Lymphoma in the US

Effect of Pembrolizumab Monotherapy Versus Brentuximab Vedotin (BV) on Symptoms Associated with Health-Related Quality of Life (HRQoL) in Relapsed/Refractory (R/R) Classical Hodgkin Lymphoma (cHL) in the Randomized, Phase 3, Keynote-204 Study

Effect of Pembrolizumab (Pembro) Monotherapy Versus Brentuximab Vedotin (BV) on Patients (Pts) with Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL): Exploratory Analysis of the Randomized, Phase 3 Keynote-204 Study By Prior Lines of Therapy

Phase 1-2 Study of Pembrolizumab Combined with the Anti-LAG-3 Antibody MK-4280 for the Treatment of Hematologic Malignancies

Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087

Two-Year Follow-up of Keynote-087 Study: Pembrolizumab Monotherapy in Relapsed/Refractory Classic Hodgkin Lymphoma

Pembrolizumab Antitumor Activity in Relapsed/Refractory Classical Hodgkin Lymphoma in Keynote-087: Revised Response Criteria for Malignant Lymphoma 2007 Criteria Versus Lugano 2014 Classification

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only